PubMed | Global Clinical Pharmacology and Exploratory Development Astellas Pharma Europe BV
Type: Clinical Trial, Phase I | Journal: European journal of drug metabolism and pharmacokinetics | Year: 2014
Mirabegron is a potent and selective 3-adrenoceptor agonist developed for the treatment of overactive bladder. In vitro studies demonstrated that mirabegron partly acts as a (quasi-) irreversible, metabolism-dependent inhibitor of CYP2D6. The effect of steady-state mirabegron on single doses of the sensitive CYP2D6 substrates metoprolol (100mg) and desipramine (50mg) was assessed in two open-label, one-sequence crossover studies in healthy subjects (CYP2D6 extensive metabolizers). Mirabegron 160mg/day increased metoprolol maximum plasma concentration (C max) 1.90-fold (90% confidence interval [CI] 1.54; 2.33) and total exposure (AUC0-) 3.29-fold (90% CI 2.70; 4.00) in 12 males (study 1). Mean metoprolol half-life increased from 2.96 to 4.11h. -Hydroxymetoprolol C max and AUC to last measurable concentration decreased 2.6-fold and 2.2-fold, respectively. In study 2, mirabegron 100mg/day increased desipramine C max 1.79-fold (90% CI 1.69; 1.90) and AUC0- 3.41-fold (90% CI 3.07; 3.80) in 14 males and 14 females. Mean desipramine half-life increased from 19.5 to 35.8h. C max of 2-hydroxydesipramine decreased ~twofold, while AUC increased ~1.3-fold. Desipramine was administered again 2weeks after the last mirabegron dose. Desipramine C max and AUC0- were still ~1.13-fold increased; the 90% CIs fell within the 0.80-1.25 interval. All treatments were well tolerated. In conclusion, mirabegron is a moderate CYP2D6 inhibitor (ratio and 90% CI <5.0).